FDA regulators are planning to review CBD product regulations in the coming months.
In recent years, the U.S. Food and Drug Administration (FDA) has taken a stance against selling CBD-based products because it needed more scientific evidence about the safety of such products.
However, the agency is now in the process of developing a regulatory assessment for hemp-derived products such as CBD.
In an interview with the Wall Street Journal on Tuesday, Janet Woodcock, the FDA’s Principal Deputy Commissioner and leader of the agency’s cannabis regulation efforts, expressed concern about the safety of CBD and whether current regulatory pathways for food and dietary supplements are suitable for this substance.
However, the agency is interested in determining whether it is safe to consume CBD on a daily basis for extended periods of time or during pregnancy.
Woodcock mentioned concerns about potential effects on fertility in the future, but, at the same time, his comment signalled that the agency is working to establish regulatory frameworks for the legal sale of appropriate cannabis and cannabis-derived products.
The FDA may soon review the available evidence on cannabis and will make a decision in the coming months on how to regulate CBD and other novel…